Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Observation of a cohort of 400 patients with different types of lymphomas.
A database on 400 patients diagnosed with lymphomas was built up over 20 years at Nîmes University Hospital. Biopsies were made on these tumours and all the samples were frozen.
Considering the heterogeneous nature of lymphomas, randomized clinical trials based on very precise criteria for the inclusion or non-inclusion of patients are the gold standard for studying the various sub-types of lymphomas by concentrating on homogeneous populations for which a limited number of parameters are analyzed simultaneously. However, due to the complexity of their medical situation, many patients may be excluded form these trials, thus making it difficult to obtain reliable results.
The analysis of a non-selected cohort has two main advantages: (1) to better understand the diversity of patients with lymphomas for which the recommendations are constantly evolving and (2) to analyze how, exactly, these are managed by integrating points which are currently poorly evaluated such as comorbidities and accessibility to treatment.
The aim of the study is to describe how these patients are managed and to demonstrate that not all patients are able to benefit from the official management recommendations applicable to their pathology.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival rate among patients with Hodgkin Lymphomas | The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted. | 2 years after inclusion |
| Overall survival rate among patients with Mantle-cell Lymphomas | The number of months during which the patient has survived since inclusion will be noted.If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted. | 2 years after inclusion |
| Overall survival rate among patients with Primitive Cerebral Lymphomas | The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted. | 2 years after inclusion |
| Overall survival rate among patients with Follicular Lymphomas | The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted. | 2 years after inclusion |
| Overall survival rate among patients with Marginal Zone Lymphomas | The number of months during which the patient has survived since inclusion will be noted. If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted. | 2 years after inclusion |
| Overall survival rate among patients with Waldenström's Disease |
| Measure | Description | Time Frame |
|---|---|---|
| Differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature. | The actual management of these patients will be compared with the data in the literature and any differences will be noted. | 2 years after inclusion |
| Differences between management of patients with Mantle-cell Lymphomas and data described in the literature. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The population consists of patients with lymphomas (Malignant Non-Hodgkinien and Hodgkin Lymphomas) diagnosed at Nîmes University Hospital from 1999 onwards and for whom the frozen biological samples are available. Since 2005, all patients have been registered in the Tumototek software program. Those diagnosed before this date can be found in the hospital's anatomopathological laboratory registers.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Eric JOURDAN, Dr. | Contact | 0466684033 | eric.jourdan@chu-nimes.fr |
| Name | Affiliation | Role |
|---|---|---|
| Anissa MEGZARI | CHU de Nîmes (Nîmes University Hospital) | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Nimes | Recruiting | Nîmes | Gard | 30029 | France |
Not provided
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D008258 | Waldenstrom Macroglobulinemia |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Lymphoma protocol was applied. Biopsies of lymphomas used for anatomopathological analysis, frozen and used for cytogenetic analysis if possible.
If the patient has died, the date of death recorded in the hospital file or from the INSERM CépiDC register will be noted. |
| 2 years after inclusion |
The actual management of these patients will be compared with the data in the literature and any differences will be noted. |
| 2 years after inclusion |
| Differences between management of patients with Primitive Cerebral Lymphomas and data described in the literature. | The actual management of these patients will be compared with the data in the literature and any differences will be noted. | 2 years after inclusion |
| Differences between management of patients with Follicular Lymphomas and data described in the literature. | The actual management of these patients will be compared with the data in the literature and any differences will be noted. | 2 years after inclusion |
| Differences between management of patients with Marginal Zone Lymphomas and data described in the literature. | The actual management of these patients will be compared with the data in the literature and any differences will be noted. | 2 years after inclusion |
| Differences between management of patients with Waldenström's Disease and data described in the literature. | The actual management of these patients will be compared with the data in the literature and any differences will be noted. | 2 years after inclusion |
| Reasons for differences between management of patients with Hodgkin Lymphomas actually observed and data described in the literature. | The reasons for any differences noted will be analyzed | 2 years after inclusion |
| Reasons for differences between management of patients with Mantle-cell Lymphomas actually observed and data described in the literature. | The reasons for any differences noted will be analyzed | 2 years after inclusion |
| Reasons for differences between management of patients with Primitive Cerebral Lymphomas actually observed and data described in the literature. | The reasons for any differences noted will be analyzed | 2 years after inclusion |
| Reasons for differences between management of patients with Follicular Lymphomas actually observed and data described in the literature. | The reasons for any differences noted will be analyzed | 2 years after inclusion |
| Reasons for differences between management of patients with Marginal Zone Lymphomas actually observed and data described in the literature. | The reasons for any differences noted will be analyzed | 2 years after inclusion |
| Reasons for differences between management of patients with Waldenström's Disease actually observed and data described in the literature. | The reasons for any differences noted will be analyzed | 2 years after inclusion |
| Analysis of the efficacy of treatment of patients with Hodgkin Lymphomas. | The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis. | 2 years after inclusion |
| Analysis of the efficacy of treatment of patients with Mantle-cell Lymphomas | The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis. | 2 years after inclusion |
| Analysis of the efficacy of treatment of patients with Primitive Cerebral Lymphomas | The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis. | 2 years after inclusion |
| Analysis of the efficacy of treatment of patients with Follicular Lymphomas | The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis. | 2 years after inclusion |
| Analysis of the efficacy of treatment of patients with Marginal Zone Lymphomas | The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis. | 2 years after inclusion |
| Analysis of the efficacy of treatment of patients with Waldenström's Disease | The following criteria for efficacy will be noted: overall survival, relapse, survival without relapse and refractory lymphomas. The histological type, treatment given and comorbidities noted will be included in the analysis. | 2 years after inclusion |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D054219 | Neoplasms, Plasma Cell |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006474 | Hemorrhagic Disorders |